The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Findings from a Phase I trial of the BTK degrader NX-5948 in B-cell malignancies
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on updated findings from a Phase I trial (NCT05131022) investigating the BTK degrader NX-5948 in B-cell malignancies. The findings reveal that this agent was well-tolerated, and patients had durable responses, particularly those with chronic lymphocytic leukemia (CLL), paving the way for the expanded phase of the study. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
At this ASH, we’re presenting the data on a BTK degrader. The study is called Nurix 5948 and this study was looking at all pan-B cell malignancies including diseases such as CLL, low-grade lymphomas, as well as high-grade lymphomas and some CNS lymphomas as well. The data that’s being presented now is an update on this BTK degrader and more specifically looking at the CLL population which 30 of these patients were treated with the single agent Nurix 5948...
At this ASH, we’re presenting the data on a BTK degrader. The study is called Nurix 5948 and this study was looking at all pan-B cell malignancies including diseases such as CLL, low-grade lymphomas, as well as high-grade lymphomas and some CNS lymphomas as well. The data that’s being presented now is an update on this BTK degrader and more specifically looking at the CLL population which 30 of these patients were treated with the single agent Nurix 5948. Different dose levels were analyzed and the good thing is that most patients tolerated the treatment very well and the responses have been durable and as a result of that the drug is moving on to the expanded phase of the study now and hopefully we will be seeing much more data in the coming ASH meetings.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Morphosys: Membership on an entity’s Board of Directors or advisory committees; Janssen, AbbVie, AstraZeneca, Alexion, Gilead: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
